NO20083333L - Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer - Google Patents
Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorerInfo
- Publication number
- NO20083333L NO20083333L NO20083333A NO20083333A NO20083333L NO 20083333 L NO20083333 L NO 20083333L NO 20083333 A NO20083333 A NO 20083333A NO 20083333 A NO20083333 A NO 20083333A NO 20083333 L NO20083333 L NO 20083333L
- Authority
- NO
- Norway
- Prior art keywords
- hiv integrase
- pharmacokinetics
- improving
- methods
- integrase inhibitors
- Prior art date
Links
- 229940099797 HIV integrase inhibitor Drugs 0.000 title abstract 2
- 239000003084 hiv integrase inhibitor Substances 0.000 title abstract 2
- 108010002459 HIV Integrase Proteins 0.000 abstract 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75503905P | 2005-12-30 | 2005-12-30 | |
| US75663106P | 2006-01-06 | 2006-01-06 | |
| US76390106P | 2006-02-01 | 2006-02-01 | |
| PCT/US2006/049668 WO2007079260A1 (en) | 2005-12-30 | 2006-12-29 | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083333L true NO20083333L (no) | 2008-09-29 |
Family
ID=38016698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083333A NO20083333L (no) | 2005-12-30 | 2008-07-29 | Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070219243A1 (enExample) |
| EP (2) | EP1976517A1 (enExample) |
| JP (1) | JP4676536B2 (enExample) |
| KR (3) | KR20160074018A (enExample) |
| CN (1) | CN104069108A (enExample) |
| AP (1) | AP2702A (enExample) |
| AU (1) | AU2006332664B2 (enExample) |
| BR (1) | BRPI0620865A2 (enExample) |
| CA (2) | CA2635468C (enExample) |
| EA (2) | EA018544B1 (enExample) |
| HR (1) | HRP20080313A2 (enExample) |
| IL (1) | IL192208A (enExample) |
| NO (1) | NO20083333L (enExample) |
| NZ (1) | NZ569576A (enExample) |
| SG (2) | SG170796A1 (enExample) |
| WO (1) | WO2007079260A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP2118082B1 (en) | 2007-02-23 | 2014-10-01 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| CA2692101A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism |
| AU2008270634B2 (en) * | 2007-06-29 | 2014-01-16 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| GB2470494B (en) * | 2008-01-17 | 2012-08-08 | Univ Holy Ghost Duquesne | Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS |
| EA032868B1 (ru) * | 2010-01-27 | 2019-07-31 | Вайв Хелткер Компани | Комбинация для лечения вич-инфекции |
| US8703786B2 (en) * | 2011-12-07 | 2014-04-22 | Texas Southern University | Etravirine formulations and uses thereof |
| MX344879B (es) | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| LT3019503T (lt) | 2013-07-12 | 2017-11-27 | Gilead Sciences, Inc. | Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| LT3236972T (lt) | 2014-12-26 | 2021-11-10 | Emory University | Antivirusiniai n4-hidroksicitidino dariniai |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| KR102606625B1 (ko) | 2015-11-09 | 2023-11-27 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스의 치료를 위한 치료 조성물 |
| LT3706762T (lt) | 2017-12-07 | 2024-12-27 | Emory University | N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| EP1090914B1 (en) * | 1992-12-29 | 2003-01-02 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| CA2371109C (en) * | 1999-06-04 | 2011-04-26 | Laman A. Alani | Improved pharmaceutical formulations |
| US6541515B2 (en) * | 2000-08-09 | 2003-04-01 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6407128B1 (en) * | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
| AR037797A1 (es) * | 2001-12-12 | 2004-12-01 | Tibotec Pharm Ltd | Combinacion de inhibidores de proteasa dependientes del citocromo p450 |
| AU2003301439A1 (en) | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| JP3567162B1 (ja) * | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| SI1564210T1 (sl) * | 2002-11-20 | 2010-01-29 | Japan Tobacco Inc | 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze |
| CA2513141A1 (en) * | 2003-01-27 | 2004-08-12 | Pfizer Inc. | Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use |
| JP2006528694A (ja) | 2003-05-13 | 2006-12-21 | スミスクライン ビーチャム コーポレーション | ナフチリジンインテグラーゼインヒビター |
| WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| EP1891089B1 (en) * | 2005-06-02 | 2014-11-05 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| CN105503721A (zh) * | 2006-09-12 | 2016-04-20 | 吉里德科学公司 | 制备整合酶抑制剂的方法和中间体 |
| CA2692101A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism |
| AU2008270634B2 (en) * | 2007-06-29 | 2014-01-16 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
-
2006
- 2006-12-29 EA EA200801619A patent/EA018544B1/ru unknown
- 2006-12-29 US US11/647,858 patent/US20070219243A1/en not_active Abandoned
- 2006-12-29 EP EP06848393A patent/EP1976517A1/en not_active Withdrawn
- 2006-12-29 HR HR20080313A patent/HRP20080313A2/xx not_active Application Discontinuation
- 2006-12-29 SG SG201102229-0A patent/SG170796A1/en unknown
- 2006-12-29 AP AP2008004522A patent/AP2702A/xx active
- 2006-12-29 KR KR1020167016288A patent/KR20160074018A/ko not_active Ceased
- 2006-12-29 CN CN201410249622.8A patent/CN104069108A/zh active Pending
- 2006-12-29 CA CA2635468A patent/CA2635468C/en active Active
- 2006-12-29 NZ NZ569576A patent/NZ569576A/en unknown
- 2006-12-29 KR KR1020147014797A patent/KR20140082858A/ko not_active Ceased
- 2006-12-29 WO PCT/US2006/049668 patent/WO2007079260A1/en not_active Ceased
- 2006-12-29 EA EA201201496A patent/EA201201496A1/ru unknown
- 2006-12-29 CA CA2847871A patent/CA2847871C/en active Active
- 2006-12-29 KR KR1020087018651A patent/KR101524165B1/ko active Active
- 2006-12-29 BR BRPI0620865-7A patent/BRPI0620865A2/pt not_active IP Right Cessation
- 2006-12-29 JP JP2008548784A patent/JP4676536B2/ja active Active
- 2006-12-29 EP EP20100193364 patent/EP2308490A1/en not_active Withdrawn
- 2006-12-29 AU AU2006332664A patent/AU2006332664B2/en active Active
- 2006-12-29 SG SG201102227-4A patent/SG170795A1/en unknown
-
2008
- 2008-06-16 IL IL192208A patent/IL192208A/en active IP Right Grant
- 2008-07-29 NO NO20083333A patent/NO20083333L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AP2008004522A0 (en) | 2008-06-30 |
| CA2635468A1 (en) | 2007-07-12 |
| KR20140082858A (ko) | 2014-07-02 |
| JP4676536B2 (ja) | 2011-04-27 |
| WO2007079260A9 (en) | 2007-08-30 |
| JP2009525265A (ja) | 2009-07-09 |
| EA200801619A1 (ru) | 2008-10-30 |
| SG170795A1 (en) | 2011-05-30 |
| CA2847871C (en) | 2016-07-26 |
| KR20160074018A (ko) | 2016-06-27 |
| CA2847871A1 (en) | 2007-07-12 |
| EA201201496A1 (ru) | 2013-07-30 |
| HRP20080313A2 (en) | 2008-11-30 |
| AU2006332664B2 (en) | 2013-03-14 |
| EA018544B1 (ru) | 2013-08-30 |
| EP1976517A1 (en) | 2008-10-08 |
| SG170796A1 (en) | 2011-05-30 |
| CA2635468C (en) | 2016-08-09 |
| NZ569576A (en) | 2011-09-30 |
| IL192208A0 (en) | 2009-02-11 |
| EP2308490A1 (en) | 2011-04-13 |
| AU2006332664A1 (en) | 2007-07-12 |
| AP2702A (en) | 2013-07-23 |
| WO2007079260A1 (en) | 2007-07-12 |
| US20070219243A1 (en) | 2007-09-20 |
| IL192208A (en) | 2013-10-31 |
| BRPI0620865A2 (pt) | 2011-11-29 |
| CN104069108A (zh) | 2014-10-01 |
| KR20080081358A (ko) | 2008-09-09 |
| KR101524165B1 (ko) | 2015-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083333L (no) | Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer | |
| UA89220C2 (ru) | Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы | |
| BRPI1011838A2 (pt) | composto de carboxamida heterocíclica de diamino | |
| WO2017109488A8 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
| NO20063958L (no) | HIV integrase inhibitorer | |
| ATE534645T1 (de) | Kaliumsalz eines hiv-integrasehemmers | |
| NZ593012A (en) | Heterocyclic aspartyl protease inhibitors and their combination with cholinesterase inhibitors or muscarinic antagonists | |
| BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| LTC1874117I2 (lt) | Policiklinis karbamoilpiridono darinys turintis živ integrazės slopinimo aktyvumą | |
| NO20070751L (no) | Inhibitorer av HCV-replifikasjon | |
| NO20064555L (no) | HIV-integraseinhibitorer. | |
| WO2004073623A3 (en) | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions | |
| ATE461202T1 (de) | Hiv-integrasehemmer | |
| WO2003065987A3 (en) | Granzyme b inhibitors | |
| CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| WO2007059230A3 (en) | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors | |
| WO2008048121A3 (en) | Macrocyclic cysteine protease inhibitors and compositions thereof | |
| EA200801200A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ | |
| WO2007019098A3 (en) | Hiv integrase inhibitors | |
| WO2006124684A3 (en) | Combination therapy comprising a taxane and a thymidylate synthase inhibitor | |
| WO2009106599A3 (en) | Substituted piperidines as therapeutic compounds | |
| MX2010010876A (es) | Piperidinas sustituidas como compuestos terapeuticos. | |
| WO2004101512A3 (en) | Naphthyridine integrase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |